Aurinia Pharmaceuticals Inc (AUPH) delivered better-than-expected financial results for the third quarter of fiscal 2025. The company reported earnings per share (EPS) of $0.23, exceeding Wall Street's consensus estimate of $0.16 by $0.07. Revenue matched expectations at $0.1 billion.
This update provides insight into Aurinia's operational performance and financial health. The firm, headquartered in Edmonton, Alberta, focuses on developing therapies for autoimmune diseases with high unmet medical needs. Its flagship product, LUPKYNIS (voclosporin), is an oral therapy for treating active lupus nephritis in adults. The company continues to advance its clinical and regulatory initiatives to support the LUPKYNIS development program and is also developing aritinercept (AUR200), aimed at treating various autoimmune conditions.
Aurinia will host an earnings conference call to discuss these results further and provide additional commentary on its business performance. Investors are encouraged to review the complete earnings release and listen to management's insights for a comprehensive understanding of the quarter's achievements and future outlook.
As of November 8, 2025, Aurinia's market capitalization stands at $1.96 billion, with a trailing P/E ratio of 32.39 and a TTM EPS of 0.43. Looking ahead, the company is set to report its next earnings on July 28, 2026, with an estimated EPS of 0.1734 and revenue expectations of $0.1 billion.